Alexion Pharma (ALXN) Announces Restructuring, Including Workforce Reduction of 20%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Alexion Announces Restructuring to Advance Corporate Strategy
September 12, 2017 8:00 AM EDTExpect to Deliver Approximately $270 Million in GAAP and Approximately $250 Million in Non-GAAP Pre-tax Savings Annually by 2019 Global Workforce Reduction of Approximately 20% Expect to Reinvest Approximately $100 Million Annually to Build Pipeline Through Disciplined Business Development and Additional Complement Indications Maximize Leadership in Complement and Grow Rare Disease Business by Focusing Investments in Priority Growth Areas Research Center of Excellence to be Based in New Haven, CT New Headquarters in Boston, MA to Support Innovation and Future Growth... More
Alexion to Host Call to Discuss Restructuring to Advance Corporate Strategy at 8:30 a.m. on September 12, 2017
September 11, 2017 4:15 PM EDTNEW HAVEN, Conn.--(BUSINESS WIRE)-- Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that the Company will issue a press release on its restructuring to advance its corporate strategy on Tuesday, September 12, 2017 at 8:00 a.m. ET. Following the release, Alexion management will conduct a... More
